Epratuzumab

DB04958

biotech investigational

Deskripsi

Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

412 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Epratuzumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Epratuzumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Epratuzumab.
Estrone Estrone may increase the thrombogenic activities of Epratuzumab.
Estradiol Estradiol may increase the thrombogenic activities of Epratuzumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Epratuzumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Epratuzumab.
Mestranol Mestranol may increase the thrombogenic activities of Epratuzumab.
Estriol Estriol may increase the thrombogenic activities of Epratuzumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Epratuzumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Epratuzumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Epratuzumab.
Tibolone Tibolone may increase the thrombogenic activities of Epratuzumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Epratuzumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Epratuzumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Epratuzumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Epratuzumab.
Zeranol Zeranol may increase the thrombogenic activities of Epratuzumab.
Equol Equol may increase the thrombogenic activities of Epratuzumab.
Promestriene Promestriene may increase the thrombogenic activities of Epratuzumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Epratuzumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Epratuzumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Epratuzumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Epratuzumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Epratuzumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Epratuzumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Epratuzumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Epratuzumab.
Formononetin Formononetin may increase the thrombogenic activities of Epratuzumab.
Estetrol Estetrol may increase the thrombogenic activities of Epratuzumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Epratuzumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Epratuzumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Epratuzumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Epratuzumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Epratuzumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Epratuzumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Epratuzumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Epratuzumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Epratuzumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Epratuzumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Epratuzumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Epratuzumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Epratuzumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Epratuzumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Epratuzumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Epratuzumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Epratuzumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Epratuzumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Epratuzumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Epratuzumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Epratuzumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Epratuzumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Epratuzumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Epratuzumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Epratuzumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Epratuzumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Epratuzumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Epratuzumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Epratuzumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Epratuzumab.
Bectumomab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Bectumomab.
Oregovomab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Oregovomab.
IGN311 The risk or severity of adverse effects can be increased when Epratuzumab is combined with IGN311.
Adecatumumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Adecatumumab.
Labetuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Labetuzumab.
Matuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Matuzumab.
Fontolizumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Fontolizumab.
Bavituximab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Bavituximab.
CR002 The risk or severity of adverse effects can be increased when Epratuzumab is combined with CR002.
Rozrolimupab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Rozrolimupab.
Girentuximab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Girentuximab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Obiltoxaximab.
XTL-001 The risk or severity of adverse effects can be increased when Epratuzumab is combined with XTL-001.
NAV 1800 The risk or severity of adverse effects can be increased when Epratuzumab is combined with NAV 1800.
Briakinumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Briakinumab.
Otelixizumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Otelixizumab.
AMG 108 The risk or severity of adverse effects can be increased when Epratuzumab is combined with AMG 108.
Iratumumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Iratumumab.
Enokizumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Enokizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Ramucirumab.
Farletuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Farletuzumab.
Veltuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Veltuzumab.
Ustekinumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Ustekinumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Epratuzumab is combined with Trastuzumab emtansine.
PRO-542 The risk or severity of adverse effects can be increased when Epratuzumab is combined with PRO-542.
TNX-901 The risk or severity of adverse effects can be increased when Epratuzumab is combined with TNX-901.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Epratuzumab is combined with Inotuzumab ozogamicin.
RI 624 The risk or severity of adverse effects can be increased when Epratuzumab is combined with RI 624.
Stamulumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with MYO-029.
CT-011 The risk or severity of adverse effects can be increased when Epratuzumab is combined with CT-011.
Leronlimab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Leronlimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Epratuzumab is combined with Glembatumumab vedotin.
Olaratumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Olaratumab.
IPH 2101 The risk or severity of adverse effects can be increased when Epratuzumab is combined with IPH 2101.
TB-402 The risk or severity of adverse effects can be increased when Epratuzumab is combined with TB-402.
Caplacizumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Caplacizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when Epratuzumab is combined with IMC-1C11.
Eldelumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Eldelumab.
Lumiliximab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Lumiliximab.
Canakinumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Canakinumab.

Target Protein

B-cell receptor CD22 CD22

Referensi & Sumber

Artikel (PubMed)
  • PMID: 16864854
    Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA: Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006 Aug 20;24(24):3880-6. Epub 2006 Jul 24.
  • PMID: 16918261
    Steinfeld SD, Youinou P: Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases. Expert Opin Biol Ther. 2006 Sep;6(9):943-9.
  • PMID: 17069520
    Goldenberg DM: Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53.
  • PMID: 18473018
    Dorner T, Goldenberg DM: Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag. 2007 Oct;3(5):953-9.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • LymphoCide

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul